Saito Y, Serizawa H, Kato Y, Nakano M, Nakamura M, Saito H, Suzuki H, Kanai T. First-line eradication for Helicobacter pylori-positive gastritis by esomeprazole-based triple therapy is influenced by CYP2C19 genotype. World J Gastroenterol 2015; 21(48): 13548-13554 [PMID: 26730167 DOI: 10.3748/wjg.v21.i48.13548]
Corresponding Author of This Article
Yoshimasa Saito, MD, PhD, Division of Pharmacotherapeutics, Keio University Faculty of Pharmacy, 1-5-30 Shibakoen, Minato-ku, Tokyo 105-8512, Japan. saito-ys@pha.keio.ac.jp
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Clinical Trials Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Dec 28, 2015; 21(48): 13548-13554 Published online Dec 28, 2015. doi: 10.3748/wjg.v21.i48.13548
Table 1 Serum pepsinogen level and Helicobacter pylori eradication in the extensive metabolizer group (CYP2C19 genotype: *1/*1)
Case
Age
Sex
PGI/II
UBT
Eradication
Before eradication
After eradication
E1
45
F
3.6
-
5.0
-
0.1
○
E2
39
M
3.3
-
6.7
-
0.4
○
E3
59
M
3.1
-
5.2
-
0.5
○
E4
58
M
2.9
-
7.1
-
0.4
○
E5
50
F
2.2
1+
5.1
-
0.3
○
E6
43
F
2.2
1+
4.9
-
0.3
○
E7
63
F
1.6
1+
4.1
-
0.0
○
E8
56
F
2.8
2+
4.1
-
0.3
○
E9
36
F
2.2
2+
4.6
-
0.0
○
E10
75
F
2.5
2+
4.8
-
0.9
○
E11
67
M
3.7
-
2.2
2+
0.0
○
E12
64
M
0.8
3+
2.2
2+
1.3
○
E13
48
M
3.4
-
3.1
-
12.7
×
E14
50
F
4.3
-
6.4
-
12.7
×
E15
67
M
3.5
-
3.7
-
41.6
×
E16
34
F
3.0
-
3.4
-
19.5
×
E17
63
M
3.1
-
3.0
-
26.8
×
E18
71
F
1.2
3+
3.1
-
11.0
×
E19
55
M
2.4
1+
2.6
1+
24.6
×
E20
56
M
2.0
2+
2.2
1+
24.9
×
E21
80
M
1.7
2+
1.8
2+
20.9
×
E22
53
M
2.2
2+
2.2
2+
26.6
×
E23
43
F
2.2
2+
2.3
2+
11.5
×
Table 2 Serum pepsinogen level and Helicobacter pylori eradication in the intermediate metabolizer group (CYP2C19 genotype: *1/*2, *1/*3)
Case
Age
Sex
CYP2C19 genotype
PGI/II
UBT
Eradication
Before eradication
After eradication
I1
61
F
*1/*2
2.6
-
4.5
-
1.1
○
I2
66
M
*1/*2
3.6
-
6.0
-
0.0
○
I3
65
F
*1/*2
2.5
-
4.1
-
0.2
○
I4
71
F
*1/*2
3.5
-
7.4
-
0.9
○
I5
59
M
*1/*3
2.2
-
5.3
-
1.1
○
I6
62
M
*1/*3
3.3
-
8.3
-
0.0
○
I7
67
M
*1/*2
4.9
-
5.0
-
0.3
○
I8
64
F
*1/*2
2.8
-
5.2
-
0.5
○
I9
64
F
*1/*2
3.2
-
5.4
-
0.1
○
I10
34
M
*1/*2
3.1
-
6.9
-
0.3
○
I11
52
M
*1/*2
3.7
-
4.9
-
0.8
○
I12
64
M
*1/*2
3.6
-
4.5
-
0.2
○
I13
55
M
*1/*3
2.0
-
4.7
-
1.1
○
I14
58
M
*1/*2
3.8
-
9.4
-
0.6
○
I15
66
F
*1/*3
1.4
-
3.7
-
1.0
○
I16
47
M
*1/*2
4.0
-
5.4
-
0.0
○
I17
42
M
*1/*3
2.8
1+
5.3
-
0.4
○
I18
53
M
*1/*2
2.3
1+
3.7
-
0.8
○
I19
56
M
*1/*3
2.0
1+
4.0
-
2.4
○
I20
51
F
*1/*2
1.1
1+
3.3
-
0.0
○
I21
62
F
*1/*2
2.3
1+
4.1
-
0.3
○
I22
39
F
*1/*2
2.7
2+
6.0
-
0.4
○
I23
63
F
*1/*3
2.1
2+
4.0
-
0.1
○
I24
53
F
*1/*2
2.3
2+
4.1
-
0.3
○
I25
45
M
*1/*2
2.4
2+
4.9
-
0.6
○
I26
55
M
*1/*2
2.6
2+
4.2
-
0.5
○
I27
50
M
*1/*2
1.8
2+
3.9
-
0.6
○
I28
55
M
*1/*2
1.3
3+
3.6
-
0.0
○
I29
53
F
*1/*2
1.7
2+
2.9
2+
0.4
○
I30
64
M
*1/*2
1.2
3+
2.5
2+
1.5
○
I31
66
F
*1/*2
0.8
3+
0.8
3+
1.4
○
I32
53
M
*1/*3
4.1
-
4.5
-
49.8
×
I33
61
M
*1/*2
4.2
-
3.2
-
24.8
×
I34
44
F
*1/*2
3.2
-
3.2
-
44.5
×
I35
51
F
*1/*2
2.4
2+
3.1
-
21.7
×
I36
28
F
*1/*3
2.2
-
2.2
1+
43.6
×
I37
70
M
*1/*3
2.7
1+
2.7
1+
9.3
×
I38
70
F
*1/*2
2.5
1+
2.0
1+
39.2
×
I39
65
M
*1/*3
3.1
-
3.0
2+
28.0
×
I40
45
F
*1/*3
2.8
-
2.5
2+
13.0
×
I41
78
F
*1/*2
0.8
3+
1.4
3+
4.1
×
I42
45
F
*1/*2
1.5
3+
1.6
3+
17.0
×
I43
70
M
*1/*3
1.1
3+
1.1
3+
37.4
×
Table 3 Serum pepsinogen level and Helicobacter pylori eradication in the poor metabolizer group (CYP2C19 genotype: *2/*2, *2/*3, *3/*3)
Case
Age
Sex
CYP2C19 genotype
PGI/II
UBT
Eradication
Before eradication
After eradication
P1
64
F
*2/*2
3.6
-
5.8
-
0.2
○
P2
46
M
*2/*2
4.0
-
5.5
-
1.2
○
P3
64
F
*2/*2
2.2
1+
3.8
-
1.1
○
P4
63
F
*2/*2
2.1
2+
3.9
-
0.0
○
P5
62
F
*2/*3
2.3
2+
4.2
-
0.2
○
P6
64
M
*2/*3
2.2
2+
5.0
-
0.0
○
P7
63
M
*2/*2
2.7
2+
4.9
-
1.2
○
P8
77
F
*3/*3
1.7
3+
2.9
2+
0.1
○
P9
68
M
*2/*2
1.3
2+
1.9
3+
1.2
○
P10
60
M
*2/*2
0.6
3+
1.4
3+
0.8
○
P11
57
M
*2/*2
4.1
-
ND
ND
0.2
○
P12
65
F
*2/*2
2.0
1+
2.0
1+
30.2
×
P13
38
F
*2/*2
2.3
2+
2.5
1+
63.8
×
Table 4 Correlation between pepsinogen I/II ratio and Helicobacter pylori eradication
Eradication
PGI/II ratio
Total
Increase
No change
Decrease
Success
26
26
1
53
Failure
4
18
3
25
Total
30
44
4
78
Table 5 Multiple logistic regression analysis to identify independent predictors associated with Helicobacter pylori eradication
Variable
P value
CYP2C19 genotype (EM vs non-EM)
0.048
Age
0.603
Sex
0.637
Pepsinogen I/II before eradication
0.809
Citation: Saito Y, Serizawa H, Kato Y, Nakano M, Nakamura M, Saito H, Suzuki H, Kanai T. First-line eradication for Helicobacter pylori-positive gastritis by esomeprazole-based triple therapy is influenced by CYP2C19 genotype. World J Gastroenterol 2015; 21(48): 13548-13554